Atlas Antibodies

Evitria AG is a biotechnology company based in Schlieren, Switzerland, specializing in the research, development, and production of protein design and expression products. The firm focuses on CHO-based transient expression of antibodies, including bispecific and fusion antibodies, and offers a robust protein expression platform that facilitates the rapid production of significant quantities of protein using HEK293 and CHO cells. With a proven track record of over 30,000 transfections and more than 5,000 antibodies and antibody-based molecules expressed and purified, Evitria serves a diverse clientele, including academic laboratories, small biotech start-ups, and major biopharmaceutical companies across the Americas, Europe, Asia, and Australia. The company's expertise enables clients to efficiently manage antibody production and address capacity challenges in their projects. Founded in 2010, Evitria continues to provide high-quality services in the field of protein expression and gene transfer.

HistoCyte Laboratories specializes in providing control materials for immunohistochemical assays utilized in cancer diagnosis. Established in 2014, the company has carved out a notable presence in key markets, including the UK and USA. HistoCyte Laboratories has developed innovative technology that employs cell lines to create tissue-like controls, which enhance the accuracy and reliability of diagnostic tests. These controls are produced to a consistent standard and come with an inexhaustible supply, addressing common challenges faced in laboratory settings. The company's primary goal is to offer cost-effective control materials that help laboratories improve the confidence in their results, thereby enhancing the overall quality of their diagnostic services. As the acceptance of cell line controls continues to grow, HistoCyte Laboratories is poised for significant expansion in its market reach.